Literature DB >> 16533341

The effect of interleukin-17 on the proliferation and invasion of JEG-3 human choriocarcinoma cells.

Sutatip Pongcharoen1, Pannika Niumsup, Donruedee Sanguansermsri, Kwansuda Supalap, Puntharee Butkhamchot.   

Abstract

PROBLEM: As there has been a study in mice showing the expression of IL-17 by decidual cells and the status of IL-17 receptor expression in human pregnancy is not known, we hypothesized that IL-17 may regulate human trophoblast proliferation and invasion. METHOD OF STUDY: JEG-3 cell line was used as a model for human trophoblast. Immunohistochemitry and reverse transcriptase polymerase chain reaction techniques were used to identify IL-17 receptor protein and mRNA, respectively. The effects of IL-17 on JEG-3 cell proliferation and invasion were tested using the BrdU incorporation and the Matrigel invasion assays, respectively.
RESULTS: IL-17 increased the invasive capacity of JEG-3 cells but had no effect on the proliferation and multinucleated formation of JEG-3 cells.
CONCLUSION: In this JEG-3 cell model of human trophoblast, the IL-17R and IL-17 may have a regulatory role in trophoblast invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533341     DOI: 10.1111/j.1600-0897.2006.00366.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  14 in total

1.  The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.

Authors:  Lubin Qiu; Dongsheng He; Xiang Fan; Zhi Li; Chuangxin Liao; Yonghong Zhu; Haijun Wang
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

2.  Decidual stromal cells recruit Th17 cells into decidua to promote proliferation and invasion of human trophoblast cells by secreting IL-17.

Authors:  Hai-Xia Wu; Li-Ping Jin; Bing Xu; Shan-Shan Liang; Da-Jin Li
Journal:  Cell Mol Immunol       Date:  2014-03-17       Impact factor: 11.530

Review 3.  TH17 cells in human recurrent pregnancy loss and pre-eclampsia.

Authors:  Binqing Fu; Zhigang Tian; Haiming Wei
Journal:  Cell Mol Immunol       Date:  2014-07-14       Impact factor: 11.530

4.  High-dose interferon-γ promotes abortion in mice by suppressing Treg and Th17 polarization.

Authors:  Hai-Yan Liu; Zhen-Kun Liu; Huhe Chao; Zhongyin Li; Zhihui Song; Ying Yang; Jing-Pian Peng
Journal:  J Interferon Cytokine Res       Date:  2013-12-20       Impact factor: 2.607

Review 5.  Molecular Cross-Talk at the Feto-Maternal Interface.

Authors:  Gendie E Lash
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-18       Impact factor: 6.915

6.  IL-17 producing innate lymphoid cells 3 (ILC3) but not Th17 cells might be the potential danger factor for preeclampsia and other pregnancy associated diseases.

Authors:  Prince A Barnie; Xin Lin; Yueqin Liu; Huaxi Xu; Zhaoliang Su
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Quantifying the biomechanics of conception: L-selectin-mediated blastocyst implantation mechanics with engineered "trophospheres".

Authors:  Robert W Yucha; Monika Jost; Dianne Rothstein; Noreen Robertson; Michele S Marcolongo
Journal:  Tissue Eng Part A       Date:  2013-10-12       Impact factor: 3.845

Review 8.  TH17- and IL-17- mediated autoantibodies and placental oxidative stress play a role in the pathophysiology of pre-eclampsia.

Authors:  D C Cornelius; B Lamarca
Journal:  Minerva Ginecol       Date:  2014-06

9.  Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma.

Authors:  Claire Galand; Sabrina Donnou; Lucile Crozet; Séverine Brunet; Valérie Touitou; Hanane Ouakrim; Wolf Herman Fridman; Catherine Sautès-Fridman; Sylvain Fisson
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

10.  IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines.

Authors:  XingWu Zhu; Lori A Mulcahy; Rabab A A Mohammed; Andrew H S Lee; Hester A Franks; Laura Kilpatrick; Acelya Yilmazer; E Claire Paish; Ian O Ellis; Poulam M Patel; Andrew M Jackson
Journal:  Breast Cancer Res       Date:  2008-11-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.